Systemic therapeutic strategies for hepatocellular carcinoma: current status and prospects
10.3760/cma.j.cn501113-20240412-00200
- VernacularTitle:肝细胞癌系统治疗策略：现状和前景
- Author:
Zhengang YUAN
1
;
Shenglong YE
Author Information
1. 海军军医大学第三附属医院肿瘤科，上海 200438
- Keywords:
Hepatocellular carcinoma;
Treatment;
Prognosis;
Efficacy;
Immunotherapy;
Second-line treatment
- From:
Chinese Journal of Hepatology
2024;32(6):565-571
- CountryChina
- Language:Chinese
-
Abstract:
Hepatocellular carcinoma (HCC) is a common type of poorly prognosticated malignant tumor. Surgical resection is the preferred treatment method for early-stage HCC. However, at the time of the initial diagnosis, fewer than 30% of patients with liver cancer are suitable for radical therapy. Systemic therapy plays an important role in the treatment process of patients with intermediate- to advanced-stage HCC, as it can effectively extend patients’ survival time. With an emphasis on the status and role of systemic therapy for comprehensive management of HCC, this article summarizes the latest progress at home and abroad in the past five years, including first-line combined immunotherapy for advanced-stage HCC, second-line therapy selection, perioperative systemic therapy application, and combined therapy of systemic and local. Currently, the treatment model combined with local therapy has already become a new research hotspot in the treatment of advanced-stage HCC. Nevertheless, in the future, individualized and precise systemic therapeutic strategies will need further exploration.
